Types of cardiomyopathy
Cardiomyopathy is disease of the heart muscle itself — not coronary artery disease or valve disease. Main types:
- Dilated cardiomyopathy (DCM):Ventricular dilation with systolic dysfunction (reduced ejection fraction). Causes: idiopathic, genetic, viral myocarditis, alcohol, chemotherapy (anthracyclines), iron overload.
- Hypertrophic cardiomyopathy (HCM):Ventricular wall thickening, often genetic (sarcomere mutations). The most common cause of sudden cardiac death in young athletes.
- Ischaemic cardiomyopathy:Ventricular dysfunction from prior myocardial infarction(s). Shares mechanisms with DCM.
NADPH oxidase in cardiac myocytes
NOX2 and NOX4 are expressed in cardiac myocytes and are elevated in all forms of cardiomyopathy:
- NOX2 is activated by neurohormonal stress (angiotensin II, endothelin-1) — generating superoxide that activates NF-κB, driving myocardial fibrosis and hypertrophy
- NOX4 is constitutively elevated in failing myocardium — contributing to mitochondrial oxidative stress and impaired energy metabolism in cardiomyocytes
- NADPH oxidase-derived ROS oxidise the ryanodine receptor (RyR2), causing calcium leak from the sarcoplasmic reticulum — contributing to arrhythmia risk and systolic dysfunction
Phycocyanobilin inhibits both NOX2 and NOX4. In rat DCM models (doxorubicin-induced and pressure overload models), spirulina supplementation reduces:
- Cardiac NADPH oxidase activity and superoxide levels
- Myocardial NF-κB activation and TNF-α/IL-6 production
- Hydroxyproline content (marker of cardiac fibrosis)
- Cardiomyocyte apoptosis
No human cardiomyopathy RCT with spirulina exists. The animal model evidence is consistent and mechanistically specific.
Anthracycline cardiotoxicity
Doxorubicin and other anthracycline chemotherapy agents cause DCM through a specific NOX2-dependent mechanism — redox cycling of the anthracycline in cardiac myocytes generates sustained superoxide production that cannot be cleared by the low catalase activity in cardiac tissue.
Phycocyanobilin’s NOX2 inhibition is directly relevant — animal data shows spirulina reduces anthracycline cardiotoxicity. However, the same antioxidant concern applies as in cancer chemotherapy generally: do not start spirulina during anthracycline treatment without oncology/cardiology team discussion. Post-chemotherapy cardiac recovery is a more clearly appropriate context.
Drug interactions in cardiomyopathy
Cardiomyopathy patients are often on complex medication regimens. Key spirulina interactions:
- Warfarin:Widely used in DCM with atrial fibrillation or low ejection fraction. Spirulina’s vitamin K1 and GLA antiplatelet effects apply — consistency principle and INR monitoring at 2–3 weeks after starting spirulina.
- Amiodarone:Amiodarone inhibits CYP2C9 and CYP3A4. Spirulina’s Nrf2 activation can modestly upregulate some CYP enzymes. The interaction is theoretical rather than documented — inform the cardiology team.
- Digoxin:Low therapeutic index. No direct spirulina-digoxin interaction is documented, but any new supplement in patients on digoxin warrants notification to the prescriber.
- Beta-blockers and ACE inhibitors/ARBs:No known pharmacokinetic interactions with spirulina. Spirulina’s blood pressure effect (−4–8 mmHg SBP) is additive — may require monitoring if already on multiple antihypertensives.
- Immunosuppressants (in myocarditis or cardiac transplant):Absolute contraindication — do not combine spirulina with calcineurin inhibitors (ciclosporin, tacrolimus) or mycophenolate without transplant cardiology approval.
Practical guidance
- Inform your cardiologist before starting spirulina — the drug interaction profile in cardiomyopathy is complex
- If cleared, start at 2–3 g/day and escalate to 5–7 g/day over 4–6 weeks
- Monitor blood pressure at home in the first 4 weeks — additive antihypertensive effect with cardiac medications
- Warfarin users: INR check at 2 weeks after starting spirulina; maintain consistent daily dose
- The most relevant populations: early-stage DCM with preserved activity; post-anthracycline cardiac recovery; ischaemic cardiomyopathy with metabolic syndrome comorbidities